Metanova Labs has leveraged Bittensor's Subnet 68 to screen approximately 4.8 million molecules against 7,000 therapeutic targets, aiming to revolutionize drug discovery through decentralized AI. The platform, known as NOVA, utilizes a global network of miners to crowdsource AI models, expanding the search space to 65 billion potential molecule-target combinations. This approach seeks to democratize drug discovery by rewarding miners for identifying promising drug candidates with effective binding and minimal toxicity. Focusing initially on mental health conditions, SN68's combinatorial method could uncover candidates overlooked by traditional screening. The blockchain infrastructure ensures transparency and manages rewards, potentially halving early-stage drug discovery costs. However, while NOVA accelerates initial screening, the subsequent costly and failure-prone stages remain unchanged. Investors are advised to monitor the progression of SN68's candidates to wet-lab validation and potential partnerships with traditional biotech firms.